Skip to main content
SpringerLink
Log in

The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: report of a synergistic effect between topotecan and radiation

  • Laboratory Investigation
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Summary

Despite innovations in imaging, surgery, and radiation therapy, local failure remains the principle clinical problem in most CNS malignancies. To date, chemotherapy has not made a major impact in the treatment of most adult CNS tumors. The inroads made by chemotherapy in pediatric CNS malignancies suggest that novel drugs, or drug combinations, may improve therapy. Topoisomerase I (Topo I) inhibitors are a relatively new group of chemotherapy drugs with a novel mechanism of action. Drugs in this group currently undergoing clinical trials are the Camptothecin analogues Topotecan, CPT-11, and 9-aminocamptothecin. There is substantial preclinical and some clinical evidence to suggest that these drugs could be useful in the treatment of CNS malignancies. Preclinical studies with the water soluble Topo I inhibitor, Topotecan, demonstrate antineoplastic activity in a variety of CNS malignancies. In addition, Topotecan has good CNS penetration in primates, and recent preliminary phase I and II clinical trials of Topotecan in pediatric and adult CNS malignancies have been promising. In this paper, we describe the unique mechanism of action, antineoplastic activity, and radiosensitizing properties of Topo I inhibitors. We present the first report demonstrating potentiation of radiation lethality by Topotecan in a human glioma (1354) cell line. The dose enhancement ratio was 3.2 at 10% survival. Thus, there is evidence to suggest that Topo I inhibitors may be beneficial in the treatment of CNS neoplasms on the basis of their antineoplastic activity alone, as well as their radiosensitizing effects. Two clinical trials which utilize concurrent Topotecan and radiation in the treatment of pediatric and adult CNS malignancies are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Fleischmann G, Pflugfelder G, Steiner EK, Javaherian K, Howard GC, Wang JC, Elgin SCR: Drosophila DNA topoisomerase I is associated with transcriptionally active regions of the genome. Proc Natl Acad Sci USA 81:6958–6962, 1984

    Google Scholar 

  2. Wang JC: DNA topoisomerases. Ann Rev Biochem 54:665–697, 1985

    Google Scholar 

  3. Li LH, Fraser TJ, Olin EJ: Action of Camptothecin on mammalian cells in culture. Cancer Res 32: 2643–2650, 1972

    Google Scholar 

  4. Wall ME, Wani MC, Cook CE, Plumer KH, McPhail AT, Sim GA: Plant antitumor agents. I. The isolation and structure of Camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Campotheca acuminata. J Amer Chem Soc 88: 3888–3890, 1966

    Google Scholar 

  5. Gottlieb JA, Luce JK: Treatment of malignant melanoma with Camptothecin (NSC-100880-. Cancer Chemother Rep 56: 03–105, 1972

    Google Scholar 

  6. Gottlieb JA, Guarino AM, Call JB: Preliminary pharmacologic and clinical evaluation of Camptothecin sodium (NSC-100880). Cancer Chemother Rep 54: 461–470, 1970

    Google Scholar 

  7. Moertel CG, Schut AJ, Reitemeier RJ: Phase II study of Camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 56: 95–101, 1972

    Google Scholar 

  8. Muggia FM, Creaven PJ, Hansen H: Phase I clinical trial of weekly and daily treatment with Camptothecin (NSC-100880): Correlation with preclinical studies. Cancer Chemother Rep 56: 515–521, 1972

    Google Scholar 

  9. Eng W, Facette L, Johnson RK, Sternglanz R: Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of Camptothecin. Mol Pharmacol 34: 755–760, 1988

    Google Scholar 

  10. Hsaing Y-H, Liu LF: Identification of mammary DNA topoisomerase I as an intra cellular target of the anti cancer drug Camptothecin. Cancer Res 48:1722–1726, 1988

    Google Scholar 

  11. Madden KR, Champoux JJ: Overexpression of human topoisomerase I in baby hamster kidney cells: hypersensitivity of clonal isolates to Camptothecin. Cancer Res 52:525–532, 1992

    Google Scholar 

  12. Mattern MR, Mong S-M, Bartus HF, Mirabelli CK, Crooke ST, Johnson RK: Relationship between the intracellular effects of Camptothecin and the inhibition of DNA topoisomerase I in cultured L1210 cells. Cancer Res 47: 1793–1798, 1987

    Google Scholar 

  13. Giovanella BC, Stehlin JS, Wall ME: DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 246:1046–1048, 1989

    Google Scholar 

  14. Kingsbury WD, Boehm JC, Jakas DR: Synthesis of water soluble (aminoalkyl) Camptothecin analogues: inhibition of topoisomerase I and anti-tumor activity. J Med Chem 34: 98–107, 1991

    Google Scholar 

  15. Kunimoto T, Nitta K, Tanaka T: Antitumor activity of 7-ethyl-10-[4-(piperidino)-1-piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of Camptothecin, against murine tumors. Cancer Res 47: 5944–5947, 1987

    Google Scholar 

  16. Matsuzaki T, Tokokura T, Mutai M: Inhibition of spontaneous and experimental metastasis by a new derivative of Camptothecin, CPT-11, in mice. Cancer Chemother Pharmacol 21: 308–312, 1988

    Google Scholar 

  17. Burris HA III, Hanouske A-R, Johnson RK: Activity of Topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Inst 84: 1816–1820, 1992

    Google Scholar 

  18. Rowinski EK, Sartorius S, Grochow L: Phase I and pharmacological study of Topotecan. A novel topoisomerase I inhibitor. J Clin Oncol 10: 647–656, 1992

    Google Scholar 

  19. Verweij J, Lund B, Beynen J: Clinical studies with Topotecan: The EORTC Experience (Abstract). Proceedings of the Seventh NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, p 118, 1992

  20. Hertzberg RP, Caranfa MJ, Hecht SM: On the mechanism of topoisomerasel inhibition by Camptothecin: Evidence for binding to an enzyme-DNA complex. Biochemistry 28: 4629–4638, 1989

    Google Scholar 

  21. Hsiang Y-H, hertzberg R, Hecht S, Liu LF: Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260:14873–14878, 1985

    Google Scholar 

  22. Avemann K, Knippers R, Koller T: Campothecin, a specific inhibitor of type I DNA topoisomerase, induces DNA breakage at replication forks. Mol Cell Biol 8: 3026–3034, 1988

    Google Scholar 

  23. Del Bino G, Lassota P, Darzynkiewicz Z: The S-phase cytotoxicity of Camptothecin. Exp Cell Res 193: 27–35, 1991

    Google Scholar 

  24. Hsaing Y-H, Lihou MG, Liu LF: Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res 49: 5077–5082, 1989

    CAS  PubMed  Google Scholar 

  25. Porter SE, Champoux JJ: The basis for camptothecin enhancement of DNA breakage by eukaryotic topoisomerase I. Nucl Acids Res 17: 8521–8532, 1989

    Google Scholar 

  26. Ryan AJ, Squires S, Strutt HL, Johnson RT: Camptothecin cytotoxicity in mammalian cells is associated with the induction of persistent double strand breaks in replicating DNA. Nucl Acids Res 19: 3295–3300, 1991

    Google Scholar 

  27. Zhang H, D'Arpa P, Liu LF: A model for tumor cell killing by topoisomerase poissons. Cancer Cells (Cold Spring Harbor) 2: 23–27, 1990

    Google Scholar 

  28. Friedman HS, Houghton PJ, Schold SC: Activity of 9-dimethylaminomethyl-l0-hydroxycamptothecin (Topotecan) against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol 34: 171–174, 1994

    Google Scholar 

  29. Blaney SM, Cole DE, Balis FM: Plasma and cerebrospinal fluid pharmacokinetic study of Topotecan in nonhuman primates. Cancer Res 53: 725–727, 1993

    Google Scholar 

  30. Pratt CB, Stewart C, Santana VM: Phase I study of Topotecan for pediatric patients with malignant solid tumors. J Clin Oncol 12: 539–543, 1994

    Google Scholar 

  31. Eisenhauer EA, Wainman N, Boos G: Phase II trials of Topotecan in patients with malignant glioma and soft tissue sarcoma (Abstract). Proc Am Soc Clin Oncol 13: 175, 1994

    Google Scholar 

  32. Boothman DA, Pardee AB: Inhibition of radiation-induced neoplastic transformation by β-lapachone. Proc Natl Acad Sci USA 86: 4963–4967, 1989

    Google Scholar 

  33. Boothman DA, Greeg S, Pardee AB: Potentiation of halogenated pyrimidine radiosensitizers in human carcinoma cells by β-lapachone (3,4-dihydro-2,2-dimethyl-2H-naphtho[1,2-b]pyran-5,6-dione), a novel DNA repair inhibitor. Cancer Res 47: 5361–5367, 1987

    Google Scholar 

  34. Boothman DA, Schlegel R, Pardee AB: Anticarcinogenic potential of DNA repair inhibitors. Mutat Res 202:393–411, 1989

    Google Scholar 

  35. Boothman DA, Wang M, Schea R, Burrows HL, Strickfaden S, Owens KJ: Posttreatment exposure to camptothecin enhances the lethal effects of X-rays on radioresistant human malignant melanoma cells. Int J Radiat Oncol Biol Phys 24: 939–948, 1992

    Google Scholar 

  36. Boothman DA: Enhanced malignant transformation is accompanied by increased survival recovery after ionizing radiation in chinese hamster embryo fibroblasts. Rad Res 138: 5121–5125, 1994

    Google Scholar 

  37. Boothman DA, Trask DK, Pardee AB: Inhibition of potentially lethal DNA damage repair in human tumor cells by β-lapachone, an activator of topoisomerase I. Cancer Res 49: 605–612, 1989

    Google Scholar 

  38. Boscia RE, Korbut T, Holden SA, Ara G, Teicher BA: Interaction of topoisomerase I inhibitors with radiation in cis-diamminedichloroplatinum (II)-sensitive and -resistant cells in vitro and in the FS all C fibrosarcoma in vivo. Int J Cancer 53: 118–123, 1993

    Google Scholar 

  39. Del Bino G, Bruno S, Yi PN, Darzynkiewicz Z: Apoptotic cell death triggered by camptothecin or teniposide. The cell cycle specificity and effects of ionizing radiation. Cell Prolif 25: 537–548, 1992

    Google Scholar 

  40. Falk SJ, Smith PJ: DNA damaging and cell cycle effects of the topoisomerase I poison camptothecin in irradiated human cells. Int J Radiat Biol 61: 749–757, 1992

    Google Scholar 

  41. Hennequin C, Giocanti N, Balosso J, Favaudon V: Interaction of ionizing radiation with the topoisomerase I poison Camptothecin in growing V-79 and HeLa cells. Cancer Res 54: 1720–1728, 1994

    Google Scholar 

  42. Kim JH, Kim SH, Kolozsvary A, Khil MS: Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by Topotecan, an inhibitor of DNA topoisomerase I. Int J Radiat Oncol Biol Phys 22:515–518, 1992

    Google Scholar 

  43. Mattern MR, Hoffman GA, McCabe FL, Johnson RK: Synergistic cell killing by ionizing radiation and the topoisomerase I inhibitor, Topotecan (SK&F 104864). Cancer Res 57: 5813–5816, 1991

    Google Scholar 

  44. Musk SR, Steele GG: The inhibition of cellular recovery in human tumour cells by inhibitors of topoisomerase. Br J Cancer 62: 364–367, 1990

    Google Scholar 

  45. Roffier SK, Chan V, Yeh MY: Potentiation of radioimmunotherapy by inhibition of topoisomerase I. Cancer Res 54: 1276–1285, 1994

    Google Scholar 

  46. Lamond JP, Wang M, Kinsella TJ, Boothman DA: Radiation lethality enhancement with 9-Aminocamptothecin: comparison to other topoisomerase I inhibitors. Int J Radiat Oncol Biol Phys (in press)

  47. Lamond JP, Wang M, Kinsella TJ, Boothman DA: Concentration and timing dependence of lethality enhancement between Topotecan, a topoisomerase I inhibitor, and ionizing radiation. Int J Radiat Oncol Biol Phys (in press)

  48. Boothman DA, Fukunaga N, Wang M: Down-regulation of topoisomerase I in mammalian cells following ionizing radiation. Cancer Res 54: 4618–4626, 1994

    Google Scholar 

  49. Hirabayashi N, Kim R, Nishiyama M: Tissue expression of topoisomerase I and II in digestive tract cancers and adjacent normal tissues (Abstract). Proc Am Assoc Cancer Res 33: 436, 1992

    Google Scholar 

  50. Husain I, Mohler JL, Seigler HF, Besterman JM: Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy. Cancer Res 54: 539–546, 1994

    Google Scholar 

  51. Van Der Zee AG, Hollema H, DeJong S: P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res 51: 5915–5920, 1991

    Google Scholar 

  52. Schiller JH, Kim K, Johnson D: Phase II study of Topotecan in extensive stage small cell lung cancer (Abstract). Proc ASCO 13: 330, 1940

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Human Oncology, University of Wisconsin-Madison, Madison, WI, USA

    John P. Lamond, Minesh P. Mehta & David A. Boothman

Authors
  1. John P. Lamond
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Minesh P. Mehta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David A. Boothman
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lamond, J.P., Mehta, M.P. & Boothman, D.A. The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: report of a synergistic effect between topotecan and radiation. J Neuro-Oncol 30, 1–6 (1996). https://doi.org/10.1007/BF00177437

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00177437

Key words

Search

Navigation